Improved effects of Carbocisteine on the residual eosinophilic inflammation in the distal airways of asthmatic patients
- Conditions
- Bronchial asthma
- Registration Number
- JPRN-UMIN000006826
- Lead Sponsor
- Tohno Area Asthma Treatment Committee (TAT Com.) in Gifu Tohno Chou Clinic Tohno Kousei Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Not provided
Patients to whom any of the following criteria apply will be excluded from the study: 1)Patients with definite COPD 2)Patients who used continuously oral steroids or short-acting beta2 receptor stimulants within one month prior to the observation phase (excluding cases when the drug was used to treat an exacerbation) 3)Patients who contracted a respiratory infection within one month prior to the observation phase 4)Patients who underwent hyposensitization therapy and used Omalizumab within three months prior to the observation phase 5)Patients with a reported adverse event related to carbocisteine 6)Patients with serious cardiac, hepatic, renal, pulmonary, or hematological disease 7)Patients who are pregnant or who are at risk of pregnancy 8)Patients with a malignancy 9)According to The Global Initiative for Asthma (GINA) 2006, patients to whom the following apply: Exacerbation:1/week Daytime asthma symptoms:More than twice weekly Limitations on activities: Yes Nocturnal or early morning symptoms: Yes Use of a bronchodilator for asthmatic attack: More than twice weekly Respiratory function (FEV1.0):more than 80% predicted value For patients who experience three or more of the abovementioned conditions per week: 10)Other patients deemed unsuitable by the principal investigator or investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method